Table 4.

Summary of antitumor activity of MORAb-004

Patient IDDose group (mg/kg/wk)Tumor type (N = 36)Cycles (n)PFS (days)Best overall responseBest % change from baseline in sum of longest diameters
101-0020.0625Colorectal253SD1
101-0040.0625Pancreatic neuroendocrine12330SD−10
101-0030.125Colorectal5127SD8
101-0050.125Colorectal124PD39
101-0060.25Colorectal4106SD0
101-0100.25Colorectal4106SD16
101-0010.5Sarcoma, uterus124aSD6
101-0110.5Mesothelioma6148aSD2
102-0010.5Colorectal adenocarcinoma250PD48
102-0040.5Carcinoid small bowel4106aSD2
101-0121Pancreatic adenocarcinoma236PD20
101-0141Colorectal adenocarcinoma129aSD3
102-0081Adenoid cystic11aNEb
102-0101Hepatocellular carcinoma15400aSD−21
102-0122Renal cell132PD29
102-0132Adenocarcinoma, unknown primary11aNEb
102-0142Myxoid chordrosarcoma4106aSD10
101-0154Colorectal adenocarcinoma256PD13
101-0164Pleural mesothelioma21aNEb
102-0154Hemangiopericytoma8222SD−13
101-0178Sarcoma137PDc
101-0188Chondrosarcoma4115SD8
102-0168Osteosarcoma, scalp259PD16
101-02212Small round cell, inguinal area113PD27
101-02312Colorectal adenocarcinoma61aNEb
101-02412Colorectal adenocarcinoma250PD1
101-02512Colorectal adenocarcinoma4106SD10
102-01912Adenocarcinoma, ampullary119PD44
102-02012Unknown primary232PDc
102-02112Non–small cell lung353aSD12
102-02412Non–small cell lung250PD23
101-01916Metastatic transitional cell, bladder250PDc
101-02016Pancreatic adenocarcinoma124PD31
101-02116Undifferentiated pleomorphic sarcoma250aSD14
102-01716Ovarian adenocarcinoma351aSD−1
102-01816Rhabdomyosarcoma8218aSD1

Abbreviations: NE, not evaluable; PD, progressive disease; SD, stable disease.

  • aCensored at last progression-free observation.

  • bNo post-baseline imaging evaluation or target lesions not evaluable.

  • cResponse was defined as PD because of the appearance of new lesions.